New Zealand has stopped new prescriptions of puberty blockers for transgender youth, citing uncertain long-term benefits and risks. The move aligns with restrictions in the UK and Scandinavia. Here’s what the new policy means, why it was introduced, and how medical groups and families are responding.
New Zealand Halts New Puberty Blocker Prescriptions for Transgender Youth Amid Global Policy Shift
TheInterviewTimes.com | 19 December 2025: New Zealand has announced a major policy shift in gender-affirming care, halting all new prescriptions of puberty-blocking medication for minors under 18. Health Minister Simeon Brown confirmed the move today, citing “significant uncertainty” about long-term safety and effectiveness — a decision that puts New Zealand in line with sweeping reforms across Europe.
The move marks one of the region’s most consequential interventions in youth gender medicine. It also comes amid escalating global scrutiny over the medical evidence behind puberty blockers, known as GnRH analogues, commonly used in early stages of gender-affirming care.
Government Cites Low-Quality Evidence and Global Reviews
Effective 19 December 2025, New Zealand will not prescribe or publicly fund the drugs for new patients seeking care for gender dysphoria. Speaking in Parliament, Brown said the government was taking a “precautionary step” to ensure that treatments remain “safe, evidence-based, and in the best interests of the young person.”
The policy is rooted in a Ministry of Health rapid evidence brief completed in September 2025. Though not yet fully released, the review reportedly concluded that the evidence supporting the use of puberty blockers for gender dysphoria is “low to very low.” The assessment mirrors conclusions from:
- The Cass Review (UK) in 2024.
- Systematic reviews conducted in Sweden, Finland, and Norway.
- Updated clinical guidance across multiple European regulatory bodies.
Associate Health Minister David Seymour and Deputy Prime Minister Winston Peters praised the move. Peters noted that restricting access to the New Puberty Blocker treatment was an explicit NZ First election commitment in 2023.
“This is about protecting vulnerable children from irreversible decisions made at a very young age,” Peters said.
Must Read: US–Russia Secretly Draft 28-Point Ukraine Peace Plan in Miami as Global Diplomacy Accelerifies
Existing Patients to Continue; Blockers Still Allowed for Other Conditions
While new prescriptions for gender dysphoria have been halted, existing patients currently on puberty blockers will continue treatment. The medication will also remain available for other established conditions such as:
- Precocious puberty
- Endometriosis
- Specific hormone-sensitive cancers
According to Te Whatu Ora, 113 young people aged 11–17 received publicly funded puberty blockers for gender dysphoria in 2023, down from 140 in 2021. Most were assigned female at birth.
Clinicians estimate that several dozen youth currently on wait-lists will now be diverted to counselling and psychological support.
Medical and Advocacy Groups Condemn the Decision
The backlash from medical and LGBTQ+ advocacy organisations was immediate.
PATHA (Professional Association for Transgender Health Aotearoa) called the announcement “a devastating blow” that would increase distress among vulnerable youth.
“These medications are safe, reversible, and life-saving when used appropriately,” co-chair Elizabeth McElrea said. “This is evidence being overridden by politics.”
Opposition leaders also criticized the measure. Rainbow Labour MP Shanan Halbert accused the government of “playing culture-war games with the lives of trans kids,” while Greens health spokesperson Ricardo Menéndez March called the move “cruel and unnecessary.”
Youth medicine specialist Dame Sue Bagshaw struck a more nuanced tone. While disappointed, she acknowledged that global evidence gaps persist.
“I’ve seen these medications give young people breathing space,” she said. “But regulators want stronger evidence — and that’s understandable.”
New National Gender Dysphoria Service Planned for 2026
The government will establish a national youth gender dysphoria service and an online information hub by mid-2026. Cross-sex hormones will remain available from age 16 under specialist supervision, though further guidelines are under review.
An interim clinical advisory group led by paediatric endocrinologist Dr Paul Hofman will oversee the transition and review exceptional cases.
New Zealand Joins European Trend Away from Early Medical Intervention
The policy places New Zealand firmly within a global trend that is moving away from the “Dutch protocol,” the early-intervention model developed in the 1990s.
Key international developments include:
- United Kingdom banning new prescriptions outside clinical trials (2024).
- Sweden, Norway, Finland significantly restricting treatment to research settings.
- United States remaining divided, with some states expanding access and others imposing outright bans.
- Australia and Canada continuing case-by-case access with evolving guidelines.
This diverging global landscape underscores the polarised debate surrounding puberty blockers.
A Growing Political and Medical Flashpoint
Supporters of the moratorium describe it as “common-sense child safeguarding.” Critics fear the move will heighten distress, increase mental-health risks, and potentially drive families abroad for continued care.
For now, New Zealand’s halt on new cases is indefinite — a pause that will remain until “robust, high-quality evidence” becomes available.
Key Takeaways
- New Zealand has halted new prescriptions of the New Puberty Blocker for transgender youth under 18.
- The decision is based on a health ministry evidence review showing low-quality data for gender dysphoria treatment.
- Existing patients will continue, and blockers remain available for other medical conditions.
- Medical groups warn of negative mental-health impacts; government says the move prioritises safety.
- New Zealand joins European nations restricting early medical interventions for gender dysphoria.